08:27 Uhr
Aktien Frankfurt Ausblick: Moderate Verluste erwartet - Henkel im Fokus

Transgene Announces Financial Calendar for 2018

Donnerstag, 21.12.2017 18:05


Regulatory News:

Transgene (Paris:TNG) today announced its financial reporting dates for 2018:

March 21:

        2017 Fiscal Year Results

April 26:

First Quarter 2018 Financial Results

May 23:

Annual Shareholders' Meeting

September 19:

First Half 2018 Financial Results

October 25:

Third Quarter 2018 Financial Results

About Transgene
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical and preclinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors). Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.
Additional information about Transgene is available at
Follow us on Twitter: @TransgeneSA

View source version on

(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.